Creative Medical Technology Holdings, Inc. CELZ 深 沪
已收盘 05-22 16:00:00 美东时间
2.39
+0.090
+3.91%
华盛通- 最 高2.395
- 今 开2.32
- 成交量 4.77万股
- 最 低 2.32
- 昨 收 2.30
- 总市值 883.50万
- 52周最高 6.25
- 市盈率 静 --
- 换手率 1.29%
- 52周最低 1.504
- 委 比 -90.41%
- 总股本 369.67万
- 历史最高 51.45
- 量 比 1.10
- 振 幅 3.26%
- 历史最低 1.504
- 每 手 1
- 风险率 0.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Creative Medical Tech Q1 EPS $(0.38) Beats $(0.39) Estimate
Creative Medical Tech (NASDAQ:CELZ) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.39) by 2.56 percent. This is a 54.22 percent increase over losses of $(0.83) per share
05-09 06:12
Pacira BioSciences Q1 2026 Earnings Call Transcript
On Thursday, Pacira BioSciences (NASDAQ:PCRX) discussed first-quarter financial...
05-01 05:27
Creative Medical Technology Announces Results From Pilot Study Of Ultrasome, Proprietary Cell-Free Regenerative Therapy For Treatment Of Osteoarthritis Of Knee
Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis MarketPHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- Creative Medical
04-28 21:04
Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline
Creative Medical Technology Holdings Inc. (CELZ) has achieved its second INN milestone with the WHO, with "etaroleucel" proposed for CELZ-101, its autologous Treg immunotherapy program. This builds on the prior INN approval of "olastrocel" for CELZ-201, highlighting the company's ability to advance multiple cell therapy programs. The milestones underscore regulatory progress and global credibility, supporting future clinical development and comme...
02-10 14:00
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 345.6% to $3.62 during...
01-20 20:05
Creative Medical Technology Holdings shares are trading higher after the company received regulatory clearance for its BioDefense burn pit program and said no additional fundraising is required to execute the initiative.
Creative Medical Technology Holdings shares are trading higher after the compan...
01-06 22:18
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced regulatory approval for its BioDefense Inc. Burn Pit Initiative, a program aimed at addressing long-term health consequences for U.S. military veterans exposed to toxic burn pits. The initiative leverages AI and induced pluripotent stem cell (iPSC) technology to build a comprehensive database and develop regenerative solutions. No additional fundraising is required, as the progra...
01-06 14:15
Creative Medical Technology Completes Patient Enrollment In FDA-Cleared ADAPT Clinical Trial For CELZ-201
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the successful completion of patient enrollment in its
2025-12-17 22:16
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
Creative Medical Technology Holdings, Inc. (CELZ) successfully completed patient enrollment in its FDA-cleared ADAPT clinical trial for CELZ-201, a cell therapy targeting chronic lower back pain. The trial met a critical milestone after an independent safety review confirmed CELZ-201's favorable safety profile. With enrollment complete, CELZ is now progressing to data analysis and后期 follow-up. CELZ-201, an "off-the-shelf" allogenic cell therapy, ...
2025-12-17 14:15
